June 07, 2012
Dr. David Raben and Dr, Antonio Jimeno, two of the country’s leading oncologists with expertise in head and neck cancer, announce a new clinical trial. Tomotherapy and will be the first time this dual biologic approach will have been performed in the US with radiation. Working closely with these investigators is Dr. John Song, one of the best otolaryngologists in Colorado with specific oncologic expertise and training and Dr. Changhu Chen in Radiation Oncology.
The clinical trial is set to last approximately 12 months and the expectation is that response rates and local-regional control will exceed our current outcomes with toxic chemo-radiation and it will be safe to administer...Previous successful clinical trials performed by Dr. Raben and Dr. Jimeno have led to good patient prognosis’ and have directed them towards this exciting new venture for head and neck cancer care. Olaparib and Cetuximab, an FDA approved anti-growth factor antibody that already improves radiation therapy effectiveness has never been attempted before in the United States. Raben is known and respected for his excellence in the industry and has contributed to more than 90 publications.
For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/6/prweb9573536.htm